FDA Grants Breakthrough Therapy Designation to Daiichi Sankyo's DS-8201 for HER2-Positive Metastatic Breast Cancer

Breakthrough Therapy designation received for the treatment of patients with HER2-positive, locally advanced or metastatic breast cancer who have been treated with trastuzumab and pertuzumab and have disease progression after ado-trastuzumab emtansine (T-D... Biopharmaceuticals, Oncology, FDA Daiichi Sankyo, Breakthrough Therapy, DS-8201, breast cancer
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news